Abstract
Control of VEGF signaling is an intense objective of pre-clinical and clinical studies in HCC disease with steadily increasing clinical application. Despite its emerging role, several aspects of anti-VEGF based treatments are poorly investigated, like the impact on tumor cells themselves, such as the effect on intracellular signaling and apoptosis induction in hepatoma cells. Effects of siRNA-VEGF on VEGF, VEGF-receptor expression and VEGF-A signaling such as AKT and JNK phosphorylation were determined under normoxic or hypoxic conditions in murine hepatoma cells. Apoptosis induction was analyzed by SubG1-fraction, JC1-staining and caspase-8 activation. VEGF receptor expression was analysed by semiquantitative real time PCR. Independent of oxygen status, siRNA-VEGF reduced VEGF levels resulting in decreased AKT and increased JNK phosphorylation in Hepa129 cells. The VEGF-receptors neuropilin-1 (Nrp1) and neuropilin-2 (Nrp2) were downregulated following siRNA-VEGF treatment or hypoxia induction respectively. Functionally, hypoxia significantly increased the apoptosis rate (as analyzed by SubG1-fraction, JC1-staining and JNKphosphorylation) which was further stimulated by siRNA-VEGF treatment. Our data indicate that antitumoral efficacy of an anti-VEGF based treatment with siRNA is partly based on negative autocrine feedback mechanisms which are even enhanced under hypoxic conditions. This observation helps to understand why antitumoral efficacy can be maintained despite of counteracting stimulation of tumoral VEGF secretion due to hypoxia. The direct impact on tumor cells further underscores the attractiveness of an anti-VEGF based siRNA treatment.
Keywords: Apoptosis, autocrine mechanisms, hepatocellular carcinoma, hypoxia, RNA interference, VEGF signaling, HCC disease, antitumoral efficacy
Current Pharmaceutical Biotechnology
Title:Combination of Hypoxia and RNA-Interference Targeting VEGF Induces Apoptosis in Hepatoma Cells Via Autocrine Mechanisms
Volume: 13 Issue: 11
Author(s): Esther Raskopf, Annabelle Vogt, Georges Decker, Sarah Hirt, Katjana Daskalow, Thorsten Cramer, Jens Standop, Maria-Angeles Gonzalez-Carmona, Tilman Sauerbruch and Volker Schmitz
Affiliation:
Keywords: Apoptosis, autocrine mechanisms, hepatocellular carcinoma, hypoxia, RNA interference, VEGF signaling, HCC disease, antitumoral efficacy
Abstract: Control of VEGF signaling is an intense objective of pre-clinical and clinical studies in HCC disease with steadily increasing clinical application. Despite its emerging role, several aspects of anti-VEGF based treatments are poorly investigated, like the impact on tumor cells themselves, such as the effect on intracellular signaling and apoptosis induction in hepatoma cells. Effects of siRNA-VEGF on VEGF, VEGF-receptor expression and VEGF-A signaling such as AKT and JNK phosphorylation were determined under normoxic or hypoxic conditions in murine hepatoma cells. Apoptosis induction was analyzed by SubG1-fraction, JC1-staining and caspase-8 activation. VEGF receptor expression was analysed by semiquantitative real time PCR. Independent of oxygen status, siRNA-VEGF reduced VEGF levels resulting in decreased AKT and increased JNK phosphorylation in Hepa129 cells. The VEGF-receptors neuropilin-1 (Nrp1) and neuropilin-2 (Nrp2) were downregulated following siRNA-VEGF treatment or hypoxia induction respectively. Functionally, hypoxia significantly increased the apoptosis rate (as analyzed by SubG1-fraction, JC1-staining and JNKphosphorylation) which was further stimulated by siRNA-VEGF treatment. Our data indicate that antitumoral efficacy of an anti-VEGF based treatment with siRNA is partly based on negative autocrine feedback mechanisms which are even enhanced under hypoxic conditions. This observation helps to understand why antitumoral efficacy can be maintained despite of counteracting stimulation of tumoral VEGF secretion due to hypoxia. The direct impact on tumor cells further underscores the attractiveness of an anti-VEGF based siRNA treatment.
Export Options
About this article
Cite this article as:
Raskopf Esther, Vogt Annabelle, Decker Georges, Hirt Sarah, Daskalow Katjana, Cramer Thorsten, Standop Jens, Gonzalez-Carmona Maria-Angeles, Sauerbruch Tilman and Schmitz Volker, Combination of Hypoxia and RNA-Interference Targeting VEGF Induces Apoptosis in Hepatoma Cells Via Autocrine Mechanisms, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802502088
DOI https://dx.doi.org/10.2174/138920112802502088 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Current Pharmaceutical Biotechnology New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease - A Translational Perspective
CNS & Neurological Disorders - Drug Targets A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Meet Our Associate Editor
MicroRNA High-Throughput Screening Technologies for Botulinum Neurotoxins
Current Topics in Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Cell Contact/Adhesion Proteins Lgl and DFak56: Tumorigenic and Whole-Organism Vital Effects Studied in Drosophila
Anti-Cancer Agents in Medicinal Chemistry New Improved Drug Delivery Technologies for Pentacyclic Triterpenes: A Review
Protein & Peptide Letters Molecular Modeling Studies of ABC Transporters Involved in Multidrug Resistance
Mini-Reviews in Medicinal Chemistry Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology A Survey of Peptides with Effective Therapeutic Potential in Alzheimer’s Disease Rodent Models or in Human Clinical Studies
Mini-Reviews in Medicinal Chemistry The Link between Exercise and Homocysteine in the Alzheimer’s Disease: A Bioinformatic Network Model
CNS & Neurological Disorders - Drug Targets APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design Grape Seed Proanthocyanidins Protect N2a Cells against Ischemic Injury via Endoplasmic Reticulum Stress and Mitochondrial-associated Pathways
CNS & Neurological Disorders - Drug Targets